Login to Your Account

Clinic Roundup

Monday, July 15, 2013
• Rxi Pharmaceuticals Corp., of Westborough, Mass., reported positive results of a Phase I study of RXI-109, an sd-rxRNA, for abnormal dermal scars.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription